NCT05182151View on ClinicalTrials.gov

Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.

TerminatedOBSERVATIONAL

Enrollment

8

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions

ApathyParkinson Disease

Interventions

DRUG

Istradefylline 40 mg

adenosine A2A receptor antagonist

Trial Locations (1)

29425

MUSC Movement Disorders Program, Charleston

Sponsors

Collaborators (1)

Kyowa Kirin, Inc.

All Listed Sponsors

collaborator

Kyowa Kirin, Inc.

INDUSTRY

lead

Medical University of South Carolina

OTHER

NCT05182151 - Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease. | Biotech Hunter | Biotech Hunter